|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Design Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Design Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
3-25-2024 Insider Buy |
Heather A. Berger
|
$3.74
CAGR »
|
$4,865.77 1,300 shares |
3-25-2024 Insider Buy |
John P. Schmid
|
$3.70
CAGR »
|
$99,738.48 26,965 shares |
9-29-2023 Insider Buy |
Rodney W. Lappe Director |
$2.35
CAGR »
|
$49,287.00 21,000 shares |
3-30-2021 Insider Buy |
Arsani William Director |
$20.00
CAGR »
|
$14,000,000.00 700,000 shares |
8-29-2023 Insider Buy |
Deepa Prasad Director |
$2.31
CAGR »
|
$27,669.60 12,000 shares |
12-20-2022 Insider Buy |
Joao Siffert, M.D. President and CEO |
$8.39
CAGR »
|
$62,503.00 7,450 shares |
12-20-2022 Insider Buy |
One Capital Fund I. Aggregator LP SR >10% Owner |
$8.42
CAGR »
|
$7,574,078.00 900,000 shares |
12-20-2022 Insider Buy |
Simeon George Director and >10% Owner |
$8.42
CAGR »
|
$7,574,078.00 900,000 shares |
12-9-2022 Insider Buy |
Rodney W. Lappe Director |
$7.96
CAGR »
|
$119,425.50 15,000 shares |
3-21-2022 Insider Buy |
Arsani William Director |
$18.99
CAGR »
|
$474,680.00 25,000 shares |
8-31-2021 Insider Buy |
Arsani William Director |
$15.45
CAGR »
|
$618,000.00 40,000 shares |
3-30-2021 Insider Buy |
One Capital Fund I. Aggregator LP SR >10% Owner |
$20.00
CAGR »
|
$5,000,000.00 250,000 shares |
3-30-2021 Insider Buy |
Pratik Shah Executive Chairperson |
$20.00
CAGR »
|
$500,000.00 25,000 shares |
3-30-2021 Insider Buy |
Stella Xu Director and >10% Owner |
$20.00
CAGR »
|
$200,000.00 10,000 shares |
3-30-2021 Insider Buy |
Simeon George Director and >10% Owner |
$20.00
CAGR »
|
$5,000,000.00 250,000 shares |
3-30-2021 Insider Buy |
Rodney W. Lappe Director |
$20.00
CAGR »
|
$100,000.00 5,000 shares |
3-30-2021 Insider Buy |
Asset Management, LP Cormorant
|
$20.00
CAGR »
|
$15,000,000.00 750,000 shares |
3-30-2021 Insider Buy |
Sean Jeffries Chief Operating Officer |
$20.00
CAGR »
|
$61,000.00 3,050 shares |
3-30-2021 Insider Buy |
Arsani William Director |
$20.00
CAGR »
|
$14,000,000.00 700,000 shares |
3-30-2021 Insider Buy |
Justin Thacker Vice President, Finance |
$20.00
CAGR »
|
$350,000.00 17,500 shares |
Also See: Institutional Holders of DSGN
Also See: SEC filings
Below we present the annualized performance delivered by Design Therapeutics stock since 3-25-2024 (the date of the most recent
insider purchase). The performance of the investment from the time Design Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about DSGN being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/26/2024 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$3.57 |
|
End price/share: |
$3.78 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
5.88% |
|
Annualized Gain: |
69.26% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,588.00 |
|
Years: |
0.08 |
|
Design Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Design Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding DSGN
|
|